🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

5,609 results for “AB” Clear

  1. Clostridium Butyricum Tablets

    The First People's Hospital of Lianyungang

    Bladder (Urothelial, Transitional Cell) Cancer

    phase 2 small molecule active

    1 trial

  2. Cognitive Behavioral Intervention

    BRIGHT MINDS BIOSCIENCES INC.

    Substance Abuse

    phase 2 other completed

    1 trial

  3. Cohort A: ORMD-0801

    ORAMED PHARMACEUTICALS INC.

    T2DM (Type 2 Diabetes Mellitus)

    phase 2 small molecule completed

    1 trial

  4. Cohort A: vilobelimab

    Edesa Biotech

    Acute Respiratory Distress Syndrome (ARDS)

    phase 2 small molecule active

    2 trials

  5. Cohort C: bevacizumab

    Edesa Biotech

    Acute Respiratory Distress Syndrome (ARDS)

    phase 2 small molecule active

    1 trial

  6. Colesevelam hydrochloride-MMX® modified-release placebo tablets, Colesevelam hydrochloride-MMX® 900 mg modified-release tablets

    Cosmo Technologies Ltd

    bile acid diarrhoea (BAD)

    phase 2 small molecule active

    1 trial

  7. Columvi 10 mg concentrate for solution for infusion, Glofitamab, Gazyvaro 1,000 mg concentrate for solution for infusion., RoActemra 20 mg/mL concentrate for solution for infusion

    Hoffmann-La Roche

    Relapsed/refractory B-cell non-Hodgkin’s lymphoma (r/r NHL)

    phase 2 small molecule active

    1 trial

  8. Combination of Bortezomib, Fludarabine and Cyclophosphamide

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Mantle Cell Lymphoma Recurrent

    phase 2 small molecule active

    1 trial

  9. Community Reinforcement Approach (CRA) + HIV prevention

    BRIGHT MINDS BIOSCIENCES INC.

    Substance Abuse

    phase 2 other completed

    1 trial

  10. Computer-based Motivational Interviewing

    BRIGHT MINDS BIOSCIENCES INC.

    Substance Abuse

    phase 2 other completed

    1 trial

  11. Cotellic 20 mg film-coated tablets, Ginisortamab

    Ningbo Cancer Hospital

    Metastatic pancreatic ductal adenocarcinoma

    phase 2 small molecule active

    1 trial

  12. Crovalimab, Crovalimab, Crovalimab Placebo F01-01, Crovalimab

    Hoffmann-La Roche

    Paroxysmal nocturnal hemoglobinuria (PNH)

    phase 2 small molecule active

    1 trial

  13. Cyclophosphamide

    Takeda

    B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1

    phase 2 small molecule active

    1 trial

  14. Cyramza 10 mg/ml concentrate for solution for infusion, Cyramza 10 mg/ml concentrate for solution for infusion, Cyramza 10 mg/ml concentrate for solution for infusion, Rilvegostomig

    AstraZeneca AB

    metastatic non-small cell lung cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  15. Cytarabine

    Hospital Authority, Hong Kong

    AML

    phase 2 small molecule active

    1 trial

  16. Cytarabine

    Kura Oncology

    Acute Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  17. Cytarabine

    Jazz Pharmaceuticals Ireland Limited

    Leukemia

    phase 2 small molecule terminated

    1 trial

  18. Cytarabine

    Teva Pharma GmbH

    Acute Myeloid Leukemia

    phase 2 small molecule terminated

    1 trial

  19. Cytarabine (Phase 1 only)

    Actinium Pharmaceuticals

    AML

    phase 2 small molecule completed

    1 trial

  20. Cytarabine and Idarubicin

    Jazz Pharmaceuticals Ireland Limited

    Acute Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  21. DABRAFENIB , TRAMETINIB

    Disc Medicine

    ANAPLASTIC THYROID CANCER

    phase 2 small molecule active

    1 trial

  22. DARATUMUMAB , BORTEZOMIB , DEXAMETHASONE

    Fondazione Telethon ETS

    Relapsed or Refractory Plasmablastic lymphoma

    phase 2 small molecule active

    1 trial

  23. DARATUMUMAB, DEXAMETHASONE, POMALIDOMIDE, DEXAMETHASONE, POMALIDOMIDE, POMALIDOMIDE, Surzetoclax, Surzetoclax, DEXAMETHASONE

    AbbVie Deutschland GmbH & Co. KG

    Multiple Myeloma (MM).

    phase 2 small molecule active

    1 trial

  24. DARZALEX 20 mg/mL concentrate for solution for infusion, DARZALEX 1800 mg solution for injection, DARZALEX 20 mg/mL concentrate for solution for infusion, VELCADE 3.5 mg powder for solution for injection, DARZALEX 20 mg/mL concentrate for solution for infusion, Venetoclax, DEXAMETHASONE

    AbbVie Deutschland GmbH & Co. KG

    Multiple Myeloma

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources